Group 1 - The company reported a revenue of HKD 695 million for the first half of 2025, representing a year-on-year increase of 5.5% [1] - The net profit for the same period was HKD 67.185 million, showing a year-on-year growth of 7.5% [1] - The company proposed an interim dividend of HKD 0.022 per share [1]

Core Viewpoint - Lee's Pharmaceutical Holdings Limited (00950) reported a revenue of HKD 695 million for the six months ending June 30, 2025, representing a year-on-year increase of 5.5% [1] - The profit attributable to the company's owners was HKD 67.185 million, reflecting a year-on-year increase of 7.5% [1] - Earnings per share were HKD 0.1141, with an interim dividend proposed at HKD 0.022 per share [1] Revenue Growth Drivers - The revenue increase was primarily driven by strong sales performance across the company's product portfolio [1] - Notable growth was observed in rare disease and specialty products, with "Qufrile" injection achieving a robust growth of 31.4% and "Buleidining" rising by 12.9% [1] - In the traditional product mix of introduced products, "Fipril" saw a significant growth of 33.3%, regaining its position as the largest contributor after last year's transitional phase [1] Impact of Procurement Programs - The centralized procurement program played a crucial role in driving revenue growth, with "Sodium Dexamethasone Injection" and "Nacogdocevir Calcium Injection" recording growth rates of 18.8% and 11.3%, respectively [1] - The improved performance of these products supported overall revenue growth and helped offset the impact of sales slowdowns in several other products during the review period [1]

Group 1 - The core viewpoint of the article highlights the steady growth of Lee's Pharmaceutical Holdings Limited, with a revenue of HKD 695 million for the first half of 2025, representing a 5.5% increase compared to the same period last year [1] - The company's profit attributable to shareholders for the first half of 2025 was HKD 67.185 million, reflecting a year-on-year increase of 7.5%, indicating a sustainable growth trajectory and strengthened operational capabilities [1] - Earnings per share for the company stood at HKD 0.1141 [1] Group 2 - The company holds a 65% stake in its subsidiary, China Oncology Medical Limited (COF), which focuses on research and development in oncology, particularly in the field of immuno-oncology therapies [1] - COF has established a robust pipeline of oncology assets, including six innovative assets and four generic drugs, developed through a combination of internal research and licensing agreements [1] - In July 2025, the injection of Socazoli was approved by the National Medical Products Administration for a new indication, marking its second approved indication after initial conditional approval for the treatment of recurrent or metastatic cervical cancer [1]

Core Viewpoint - Lee's Pharmaceutical Holdings Limited (00950) reported a revenue of HKD 695 million for the six months ending June 30, 2025, representing a year-on-year increase of 5.5% [1] - The profit attributable to the company's owners was HKD 67.185 million, up 7.5% year-on-year, with earnings per share at HKD 0.1141 and an interim dividend of HKD 0.022 per share proposed [1] Revenue Growth - The revenue increase was primarily driven by strong sales performance across the company's product portfolio [1] - Notable growth was observed in rare disease and specialty products, with a 31.4% increase in sales of the injection product Qufrener (芮旎尔®) and a 12.9% increase in Budesonide (布累迪宁®) [1] - The introduced product Fipril (菲普利®) saw a significant growth of 33.3%, regaining its position as the largest contributor after a transitional phase last year [1] Impact of Procurement Programs - The centralized procurement program played a crucial role in revenue growth, with the injection product Sodium Dexamethasone (立畅青®) and Enoxaparin Sodium (立腾菁®) achieving growth rates of 18.8% and 11.3%, respectively [1] - The improved performance of these products supported overall revenue growth and helped offset the impact of sales slowdowns in several other products during the review period [1]

第 1 頁 共 2 頁 v 1.1.1 EF001 | 發行人所發行上市權證/可轉換債券的相關信息 | | | --- | --- | | 發行人所發行上市權證/可轉換債券 | 不適用 | | 其他信息 | | | 其他信息 | 不適用 | | 發行人董事 | | | 於本公佈日期，李小芳女士（主席）及李燁妮女士為執行董事；李小羿博士、James Charles Gale先生及黃瑞瑨先生為非執行董 | | | 事；而陳友正博士、蔣綺華女士及詹華強博士為獨立非執行董事。 | | EF001 第 2 頁 共 2 頁 v 1.1.1 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | | --- | --- | | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | 股票發行人現金股息公告 | | | 發行人名稱 | 李氏大藥廠控股有限公司 | | 股份代號 | 00950 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至 ...

Financial Performance - For the six months ended June 30, 2025, the company's revenue was HKD 694,821,000, representing a year-on-year increase of 5.5% from HKD 658,345,000 in 2024[2]. - Gross profit for the same period was HKD 360,053,000, up 2.7% from HKD 350,595,000 in 2024, despite a decrease in gross margin from 53.3% to 51.8%[5]. - Net profit attributable to shareholders was HKD 67,185,000, reflecting a 7.5% increase compared to HKD 62,478,000 in the previous year[8]. - Operating profit decreased to HKD 67,515,000 from HKD 68,134,000 year-over-year, indicating a decline of approximately 0.9%[19]. - Net profit for the period was HKD 50,546,000, down from HKD 54,869,000 in 2024, a decrease of about 7.9%[20]. - Basic earnings per share for the six months ended June 30, 2025, was HKD 11.41, compared to HKD 10.61 in 2024, an increase of approximately 7.5%[19]. - The company reported a net profit attributable to shareholders of HKD 67,185,000 for the six months ended June 30, 2025, compared to HKD 62,478,000 for the same period in 2024, representing an increase of approximately 11.0%[44]. Research and Development - The company invested HKD 159,756,000 in research and development, a significant increase of 88.6% from HKD 84,713,000 in 2024, accounting for 23.0% of the revenue[6]. - Research and development expenses increased to HKD 41,611,000 from HKD 34,076,000, representing a rise of approximately 22%[31]. - The company maintains a strong project pipeline in drug development, with a focus on selecting and advancing promising opportunities across various therapeutic areas[11]. Manufacturing and Production - The company has enhanced its manufacturing capabilities with a new fully automated production line, significantly increasing production efficiency and capacity for key products[9]. - The company is focusing on improving production and manufacturing efficiency, including expanding the production scale of Aripiprazole tablets and advancing the verification batch production of the product after successful Phase II clinical trials of the fentanyl inhalation solution[10]. Market and Sales - The strong performance in rare disease and specialty products, particularly the 31.4% growth in "Rinvoq®" and 12.9% growth in "Brolucizumab®", contributed to overall revenue growth[4]. - The company reported that new product contributions accounted for approximately 39.0% of total revenue, with proprietary and generic products making up the remaining 61.0%[5]. - The company has successfully maintained sales growth, with 10 products included in the latest medical insurance drug list, reflecting efforts to expand market access and improve patient affordability[17]. - The company is cautiously optimistic about the second half of 2025, expecting more products to be considered for inclusion in the medical insurance drug list, despite potential pricing pressures from regulatory developments[18]. Financial Position - Total assets as of June 30, 2025, amounted to HKD 2,182,833,000, up from HKD 1,846,612,000 in 2024, representing an increase of about 18.2%[21]. - Non-current assets were valued at HKD 1,245,683,000, an increase from HKD 1,135,017,000 in the previous year, reflecting a growth of approximately 9.8%[21]. - Current liabilities increased to HKD 813,393,000 from HKD 771,254,000, indicating a rise of about 5.5%[21]. - The company's equity attributable to owners was HKD 1,943,441,000, compared to HKD 1,651,799,000 in 2024, an increase of approximately 17.7%[22]. - The company reported a foreign exchange gain of HKD 45,887,000 for the period, compared to a loss of HKD 27,737,000 in the previous year[20]. - The company’s total comprehensive income for the period was HKD 306,114,000, compared to HKD 62,478,000 in the previous year, showing a significant increase driven by fair value changes in financial assets[23]. Cash Flow and Investments - The cash generated from operating activities for the six months ended June 30, 2025, was HKD 192,906,000, significantly higher than HKD 67,203,000 in the previous year, indicating a substantial improvement in operational efficiency[24]. - The company incurred total cash outflows from investing activities of HKD 86,336,000 for the six months ended June 30, 2025, compared to HKD 65,206,000 in the same period of 2024, reflecting increased investment in development and capital expenditures[24]. - The company paid dividends of HKD 14,721,000 during the period, an increase from HKD 5,888,000 in the previous year, reflecting a commitment to returning value to shareholders[24]. Dividends and Shareholder Returns - The company declared an interim dividend of HKD 2.20 per share, up from HKD 2.00 in the previous year[2]. - The interim dividend declared is HKD 0.022 per ordinary share, up from HKD 0.020 per share in 2024, totaling HKD 12,954,000 compared to HKD 11,777,000 in the previous year[41]. - The company’s retained earnings increased to HKD 3,699,008,000 as of June 30, 2025, compared to HKD 3,560,525,000 at the end of June 2024, indicating growth in accumulated profits[23]. Regulatory and Compliance - The company’s financial statements were prepared in accordance with Hong Kong Financial Reporting Standards, ensuring compliance with local regulations and standards[25]. - The company’s estimated taxable profits in Hong Kong are subject to a two-tiered tax system, with profits up to HKD 2 million taxed at 8.25% and profits above that taxed at 16.5%[36]. Other Financial Metrics - The group reported segment revenue of HKD 423,504,000 for patented and generic products, an increase from HKD 402,343,000 in the previous year, representing a growth of approximately 27.5%[31]. - Revenue from introduced products was HKD 271,317,000, up from HKD 256,002,000, marking a growth of about 6%[31]. - The total amount of trade payables decreased to HKD 133,030,000 as of June 30, 2025, from HKD 141,967,000 as of December 31, 2024, a decline of about 6.3%[51]. - The company incurred current tax expenses of HKD 5,604,000 for the six months ended June 30, 2025, compared to HKD 2,319,000 for the same period in 2024, representing a significant increase of approximately 141.5%[37].

Group 1 - GL Capital Management GP Limited reduced its stake in Lee's Pharmaceutical Holdings Limited (00950.HK) by selling 2.0535 million shares at an average price of HKD 1.8958 per share, amounting to approximately HKD 3.893 million [1] - Following the sale, GL Capital Management's total shareholding decreased to 40.0365 million shares, representing a reduction in ownership from 7.15% to 6.80% [1][2]

Group 1 - GL Capital Management GP Limited reduced its stake in Lee's Pharmaceutical Holdings Limited (00950) by 205.35 thousand shares at a price of HKD 1.8958 per share, totaling approximately HKD 3.893 million [1] - After the reduction, GL Capital Management's latest holding is 40.0365 million shares, representing a 6.8% ownership stake in the company [1]

Group 1 - GL Capital Management GP Limited reduced its stake in Lee's Pharmaceutical Holdings Limited (00950) by 2.0535 million shares at a price of HKD 1.8958 per share, totaling approximately HKD 3.893 million [1] - After the reduction, the latest shareholding number is 40.0365 million shares, representing a holding percentage of 6.8% [1]

香港联交所最新数据显示，8月8日，GL Capital Management GP Limited减持李氏大药厂(00950)127.65万 股，每股作价1.87港元，总金额约为238.71万港元。减持后最新持股数目为4703.5万股，持股比例为 7.99%。 ...